Medical equipment maker Bruker Daltonik has received clearance from the US Food and Drug Administration (FDA) to market its test to detect the Candida auris (C. auris) pathogen.

The test is set to be run on the company’s Bruker Maldi Biotyper CA system, currently approved to identify 333 species or species groups across 424 clinically relevant bacteria and yeast.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

C. auris is a yeast known to result in serious infections in hospitalised patients and is mostly resistant to various antifungal drugs.

“The test will be run on the company’s Bruker Maldi Biotyper CA system, currently approved to identify 333 species or species groups across 424 clinically relevant bacteria and yeast.”

Bruker’s device employs a matrix-assisted laser desorption/ionisation (MALDI-TOF) mass spectrometry to generate an organism spectrum based on the microbes found in patient samples.

The spectrum is then cross-checked with a reference organism database to ensure correct identification.

FDA Office of In Vitro Diagnostics and Radiological Health acting director Donald St Pierre said: “The FDA has confidence in this technology and recognises the need to rapidly address outbreaks both for C. auris and for other pathogenic microorganisms to help protect Americans through the recognition and identification of emerging infectious pathogens.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Meanwhile, a research carried out by the University of Oxford in the UK revealed that multi-use of thermometers led to a previous C. auris outbreak at the university hospitals’ neurosciences intensive care unit (NICU).

The researchers reached the conclusion based on the analysis of 70 C. auris patients. It was observed that the same thermometers were used in 57 of the 66 patients infected after admission into the NICU.

University of Oxford Nuffield Department of Medicine researcher Dr David Eyre said: “Despite a bundle of infection control interventions, the outbreak was only controlled following removal of the temperature probes.

“This reinforces the need to carefully investigate the environment, and in particular multi-use patient equipment, in any unexplained healthcare-associated outbreak.”